Introduction: What they say
Noble laureate in Physiology/Medicine (1975) Prof. David Baltimore, from California Institute of Technology, California, USA, had reported in the July 8, 2014 issue of the Journal “Blood” that: “Dual mechanisms by which MiR-125b represses IRF4 to induce myeloid/B-cell leukemias.”
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-derived therapy for Human Leukemias: Grifolin, an antitumor natural product from mushroom Albatrellus confluens, suppresses B-Cell and myeloid leukemias via up regulation of the tumor suppressor IRF4
From Research findings to Therapeutic opportunity:
This study suggests that Grifolin, by increasing the expression of its target gene, it may increase the expression of a number of tumor suppressor genes, including IRF4. Thereby, it could inhibit the progression of B-Cell and myeloid leukemias (figs. 1 and 2).
Figure 1 Grifolin suppresses increases the expression IRF4 and inhibits the progression of B-Cell and myeloid leukemias via up regulation of its target gene
Figure 2. Grifolin
Figure 3. Mechanistic insight into how Naringenin increases the expression of IRF4
Taken together, this study suggests that pharmacological formulations encompassing “Grifolin or its analogues or Grifolin in combination with other anticancer drugs“ may be used to inhibit B-Cell and myeloid leukemias (fig. 3).
Details of the research details:
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed mechanistic information: How Grifolin increases the expression of IRF4?
Amount: $ 50
For purchase and payment details, you may reach us at admin@genomediscovery.org
# Research cooperation
References:
Web: http://genomediscovery.org or newbioideas.com
Citation: Boominathan, L., Natural product-derived therapy for Human Leukemias: Grifolin, an antitumor natural product from mushroom Albatrellus confluens, suppresses B-Cell and myeloid leukemias via up regulation of the tumor suppressor IRF4, 13/December/2016, 11.01 pm, Genome-2-Bio-Medicine Discovery Center.
Courtesy: When you cite drop us a line at admin@genomediscovery.org